[go: up one dir, main page]

UY37381A - Compuestos que inhiben proteasas 3c y 3cl y métodos de uso de los mismos - Google Patents

Compuestos que inhiben proteasas 3c y 3cl y métodos de uso de los mismos

Info

Publication number
UY37381A
UY37381A UY0001037381A UY37381A UY37381A UY 37381 A UY37381 A UY 37381A UY 0001037381 A UY0001037381 A UY 0001037381A UY 37381 A UY37381 A UY 37381A UY 37381 A UY37381 A UY 37381A
Authority
UY
Uruguay
Prior art keywords
compounds
methods
same
inhibit proteases
proteases
Prior art date
Application number
UY0001037381A
Other languages
English (en)
Inventor
Qi Jin
Janos Botyanszki
G CATALANO John
Yoke Chong Pek
D Dickson Hamilton
Anna Leivers
Xiangmin Liao
Andrew Maynard
John Miller
Wing-Fai TAI Vincent
Reema Thalji
Brad Shotwell John
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip No 2 Ltd filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of UY37381A publication Critical patent/UY37381A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos, específicamente inhibidores de proteasas, más específicamente inhibidores de proteasas 3C y 3CL, para el tratamiento de infecciones virales, y métodos de preparación y uso de tales compuestos.
UY0001037381A 2016-08-30 2017-08-28 Compuestos que inhiben proteasas 3c y 3cl y métodos de uso de los mismos UY37381A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662381560P 2016-08-30 2016-08-30
US201662382410P 2016-09-01 2016-09-01

Publications (1)

Publication Number Publication Date
UY37381A true UY37381A (es) 2018-03-23

Family

ID=59966793

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037381A UY37381A (es) 2016-08-30 2017-08-28 Compuestos que inhiben proteasas 3c y 3cl y métodos de uso de los mismos

Country Status (3)

Country Link
TW (1) TW201817714A (es)
UY (1) UY37381A (es)
WO (1) WO2018042343A2 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110818691A (zh) * 2018-08-09 2020-02-21 中国科学院上海药物研究所 酮酰胺类化合物及其制备方法、药物组合物和用途
WO2021151387A1 (zh) * 2020-01-31 2021-08-05 中国科学院上海药物研究所 一种酮酰胺类化合物的药物用途
WO2021191827A1 (en) 2020-03-26 2021-09-30 Glaxosmithkline Intellectual Property Development Limited Tripeptides derivatives for treating sars-cov-2 infections
CN116194114A (zh) 2020-03-26 2023-05-30 葛兰素史密斯克莱知识产权发展有限公司 用于防止或治疗病毒感染的组织蛋白酶抑制剂
WO2021206877A1 (en) * 2020-04-10 2021-10-14 Cocrystal Pharma, Inc. Inhibitors of norovirus and coronavirus replication
US20230142221A1 (en) * 2020-04-10 2023-05-11 Kamal Khan Mubarak Compositions and methods for modulating ace2 receptor
US11124497B1 (en) 2020-04-17 2021-09-21 Pardes Biosciences, Inc. Inhibitors of cysteine proteases and methods of use thereof
CA3180177A1 (en) * 2020-05-08 2021-11-11 The Board Of Trustees Of The Leland Stanford Junior University Protease inhibitors for treatment or prevention of coronavirus disease
US11174231B1 (en) 2020-06-09 2021-11-16 Pardes Biosciences, Inc. Inhibitors of cysteine proteases and methods of use thereof
EP4178955A1 (en) 2020-07-11 2023-05-17 Pfizer Inc. Antiviral heteroaryl ketone derivatives
DE21846991T1 (de) 2020-07-20 2022-07-21 Enanta Pharmaceuticals, Inc. Funktionalisierte peptide als antivirale wirkstoffe
US11351149B2 (en) * 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
US11352363B1 (en) 2020-11-23 2022-06-07 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
US11384090B2 (en) 2020-11-23 2022-07-12 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
IL302990A (en) 2020-11-23 2023-07-01 Enanta Pharm Inc Novel spiropyrrolidine derived antiviral agents
KR20230124582A (ko) 2020-11-23 2023-08-25 이난타 파마슈티칼스, 인코포레이티드 신규한 스피로피롤리딘 유래 항바이러스제
IL303757A (en) * 2020-12-18 2023-08-01 Heptares Therapeutics Ltd Sars-cov-2 mpro inhibitor compounds
WO2022208262A1 (en) * 2021-03-30 2022-10-06 Pfizer Inc. Ether-linked antiviral compounds
WO2022212707A1 (en) * 2021-04-01 2022-10-06 Primmune Therapeutics, Inc. Sars-3cl protease inhibitors
KR102695128B1 (ko) * 2021-04-16 2024-08-16 푸지엔 에이키링크 바이오테크놀로지 컴퍼니 리미티드 고리 변형된 프롤린 쇼트 펩티드 화합물 및 이의 용도
US11970502B2 (en) 2021-05-04 2024-04-30 Enanta Pharmaceuticals, Inc. Macrocyclic antiviral agents
US11319325B1 (en) 2021-05-11 2022-05-03 Enanta Pharmaceuticals, Inc. Macrocyclic spiropyrrolidine derived antiviral agents
WO2022265577A2 (en) * 2021-06-15 2022-12-22 Agency For Science, Technology And Research Coronavirus enzyme modulators, methods of synthesis and uses thereof
CA3224494A1 (en) 2021-07-09 2023-01-12 Koen Vandyck Anti-viral compounds
CN113773259A (zh) * 2021-07-14 2021-12-10 上海药明康德新药开发有限公司 病毒主蛋白酶抑制剂及其制备方法和用途
WO2023003610A1 (en) * 2021-07-23 2023-01-26 Enanta Pharmaceuticals, Inc. Novel spiropyrrolidine derived antiviral agents
US11339170B1 (en) 2021-07-23 2022-05-24 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
CN114149415A (zh) * 2021-07-26 2022-03-08 中国药科大学 一种拟肽类化合物及其衍生物、制备方法、药物组合物和应用
WO2023009187A1 (en) * 2021-07-29 2023-02-02 Enanta Pharmaceuticals, Inc. Novel spiropyrrolidine derived antiviral agents
US11325916B1 (en) 2021-07-29 2022-05-10 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
CN117836272B (zh) * 2021-08-02 2025-02-28 北京华益健康药物研究中心 用于治疗或预防冠状病毒感染的3cl蛋白酶小分子抑制剂及其用途
JP2024527057A (ja) * 2021-09-09 2024-07-19 広東衆生睿創生物科技有限公司 ケトアミド誘導体およびその用途
WO2023043816A1 (en) * 2021-09-17 2023-03-23 Aligos Therapeutics, Inc. Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections
WO2023044171A1 (en) * 2021-09-20 2023-03-23 Pardes Biosciences, Inc. Inhibitors of cysteine proteases and methods of use thereof
AU2022357033A1 (en) * 2021-09-30 2024-03-21 Hainan Simcere Pharmaceutical Co., Ltd. Cyano compound, and preparation method therefor and use thereof
US11858945B2 (en) 2021-11-12 2024-01-02 Enanta Pharmaceuticals, Inc. Alkyne-containing antiviral agents
US11912714B2 (en) 2021-11-12 2024-02-27 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
WO2023086400A1 (en) * 2021-11-12 2023-05-19 Enanta Pharmaceuticals, Inc. Novel spiropyrrolidine derived antiviral agents
US11993600B2 (en) 2021-12-08 2024-05-28 Enanta Pharmaceuticals, Inc. Saturated spirocyclics as antiviral agents
WO2023107417A1 (en) * 2021-12-08 2023-06-15 Enanta Pharmaceuticals, Inc. Heterocyclic antiviral agents
WO2023149982A1 (en) * 2022-02-07 2023-08-10 Purdue Research Foundation Compounds for the treatment of sars
CN114957383B (zh) * 2022-04-01 2024-12-31 中国科学院上海药物研究所 一种拟肽类化合物及其制备方法、药物组合物和用途
WO2023196307A1 (en) 2022-04-05 2023-10-12 Enanta Pharmaceuticals, Inc. Novel spiropyrrolidine derived antiviral agents
WO2024078302A1 (zh) * 2022-10-13 2024-04-18 广东众生睿创生物科技有限公司 一种酮酰胺衍生物的晶型以及其制备方法
WO2024078294A1 (zh) * 2022-10-13 2024-04-18 广东众生睿创生物科技有限公司 酮酰胺衍生物的无定型及其制备方法
WO2024112621A1 (en) * 2022-11-22 2024-05-30 Merck Sharp & Dohme Llc 2-amino-n-(4-amino-3,4-dioxo-1-(2-oxopyrrolidin-3-yl)butan-2-yl)benzamide derivatives as protease inhibitors for treating or preventing coronavirus infection
WO2024131615A1 (zh) * 2022-12-23 2024-06-27 广东众生睿创生物科技有限公司 一种用于治疗或缓解新冠肺炎的药物组合物及含有该药物组合物的制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3798209A (en) 1971-06-01 1974-03-19 Icn Pharmaceuticals 1,2,4-triazole nucleosides
USRE29835E (en) 1971-06-01 1978-11-14 Icn Pharmaceuticals 1,2,4-Triazole nucleosides
WO2006061714A2 (en) * 2004-12-09 2006-06-15 Pfizer Inc. Anticoronaviral compounds and compositions, their pharmaceutical uses and materials for their synthesis
GB0716292D0 (en) 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
US9474759B2 (en) * 2011-09-27 2016-10-25 Kansas State University Research Foundation Broad-spectrum antivirals against 3C or 3C-like proteases of picornavirus-like supercluster: picornaviruses, caliciviruses and coronaviruses

Also Published As

Publication number Publication date
WO2018042343A2 (en) 2018-03-08
TW201817714A (zh) 2018-05-16
WO2018042343A3 (en) 2018-04-19

Similar Documents

Publication Publication Date Title
UY37381A (es) Compuestos que inhiben proteasas 3c y 3cl y métodos de uso de los mismos
CO2021007068A2 (es) Degradadores de irak y usos de los mismos
MX2023004593A (es) Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos.
ZA201903984B (en) Methods of using thermostable serine proteases
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
BR112019012343A2 (pt) anticorpos il-11ra
CL2018000542A1 (es) Nuevos derivados de fenoximetilo.
BR112019012342A2 (pt) anticorpos il-11
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
ECSP17023281A (es) Inhibidores de mk2 y sus usos
PH12018500408A1 (en) Bicyclic compounds as atx inhibitors
MX2017005920A (es) Anticuerpos anti-tim3 y metodos de uso.
MX2018001890A (es) Compuestos biciclicos como inhibidores de autotaxina (atx).
CL2016001231A1 (es) Compuestos de inhibidor de autotaxina
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
CL2015001377A1 (es) Inhbibidores de bmi-1 primidinas sustituidas inversas
CR20150524A (es) Compuestos de heteroarilo y sus usos
MX2015011514A (es) Compuestos de heteroarilo y sus usos.
MX2022000053A (es) Moduladores de interaccion de sestrina-gator2 y sus usos.
MX2022007841A (es) Degradadores del regulador dependiente de actina asociado a la matriz relacionado con el complejo switch/sacarosa no fermentable de la subfamilia a de la cromatina (smarca)y usos de los mismos.
CL2020003083A1 (es) Inhibidores de masp-2 y métodos de uso
CL2015002897A1 (es) Inhibidores de bace1
CY1124338T1 (el) Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων
DOP2016000336A (es) Derivados de isoindolina para uso en el tratamiento de una infeccion viral
DOP2018000066A (es) Compuestos útiles para inhibir ror-gamma-t

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20230626